Breaking News
Sort by:
Top Post
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial for the Treatment of Rett Syndrome
Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene […]
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying […]
Oblato Announces the First Enrollment in a Phase 1 Clinical Trial for an Oral Formulation of OKN-007 in Recurrent High-Grade Glioma Patients
Oblato, a subsidiary company of HLB Therapeutics in Korea, has announced the first enrollment for […]
Myrtelle Announces Positive 6-month Post-Treatment Data in Patients in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease
Myrtelle, a gene therapy company focused on developing transformative treatments for neurodegenerative diseases, has announced […]
Zucara Therapeutics Receives IND Clearance for Phase 2 Clinical Trial of ZT-01
Zucara Therapeutics, a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent hypoglycemia […]
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors
IDEAYA Biosciences, a precision medicine oncology company committed to the discovery and development of targeted […]
PharmaJet Announces Government Award Expansion to Clinically Assess a DNA Vaccine Combined with its Systems
PharmaJet, a company engineering Precision Delivery Systems™ (PDS) that overcome the challenges of vaccine delivery, […]
Landmark Study Finds Pison AI Technology Can Detect Neurological Disorder in ALS Patients
Pison, the pioneers behind AI-powered neural biosensors for health, wellness, and 3D touchless smart device […]
Sapience Therapeutics to Present Late-Breaking Data on ST101 and ST316 at the American Association for Cancer Research (AACR)
Sapience Therapeutics, a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics […]
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
Amylyx Pharmaceuticals has announced that the first participant has been dosed in the HELIOS study, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more